Intrauterine Transfusion for Fetal Anemia

Intrauterine transfusion is a medical procedure that delivers blood directly to a baby while still in the womb. It treats severe fetal anemia, a condition where the developing baby has too few healthy red blood cells. Red blood cells carry oxygen throughout the body, and without enough of them, a baby's growth and development can be at serious risk.

This procedure is most often needed when blood type incompatibility causes hemolytic disease. Hemolytic disease happens when a pregnant person's immune system attacks the baby's red blood cells. This occurs when the mother and baby have different blood types, most commonly involving Rh factor or ABO blood type differences. The mother's antibodies cross the placenta and destroy the baby's red blood cells faster than the baby can replace them.

During the transfusion, doctors use ultrasound imaging to guide a thin needle through the mother's abdomen into the baby's umbilical cord or abdominal cavity. They then deliver specially prepared red blood cells that match the baby's needs. These donor cells are type O-negative, screened for viruses like cytomegalovirus, and treated with radiation to prevent complications. The procedure can be repeated multiple times if needed until the baby is ready for delivery.

Intrauterine transfusion treats a condition in the developing baby, not the pregnant person. The pregnant person typically feels no symptoms themselves. Warning signs are detected through prenatal monitoring and testing.

• Abnormal ultrasound findings showing fluid buildup in the baby's body
• Enlarged heart or liver seen on imaging
• Excessive amniotic fluid surrounding the baby
• Decreased fetal movement reported by the pregnant person
• Signs of hydrops fetalis, a severe form of fluid retention
• Fast heart rate detected during fetal monitoring
• Pale appearance of the baby on detailed ultrasound

Many cases are identified before any visible symptoms appear through routine blood type screening during pregnancy. Early detection through blood testing allows doctors to monitor at-risk pregnancies closely and intervene before severe anemia develops.

The primary cause of fetal anemia requiring intrauterine transfusion is blood type incompatibility between mother and baby. Rh incompatibility is the most common trigger. This happens when an Rh-negative mother carries an Rh-positive baby. The mother's immune system may produce antibodies that cross the placenta and attack the baby's Rh-positive red blood cells. ABO incompatibility can also cause hemolytic disease, though it is usually less severe. This occurs when a mother with type O blood carries a baby with type A or B blood.

Other risk factors include previous pregnancies where sensitization occurred, previous blood transfusions, miscarriage or abortion without proper preventive treatment, and certain prenatal procedures like amniocentesis. Infections such as parvovirus B19, genetic conditions affecting red blood cell production, and twin-to-twin transfusion syndrome can also lead to severe fetal anemia. Without early blood type screening and proper monitoring, these conditions can progress to life-threatening anemia requiring urgent intervention.

Diagnosis begins with blood type and Rh factor testing for all pregnant people during their first prenatal visit. Rite Aid offers ABO Blood Type and Rh Factor testing as an add-on to help identify potential incompatibility risks early in pregnancy. If you are Rh-negative or have a history of sensitization, your doctor will monitor antibody levels through additional blood tests called indirect Coombs tests or antibody screens throughout your pregnancy.

When antibody levels suggest the baby may be at risk, doctors use specialized ultrasound called Doppler imaging to measure blood flow in the baby's brain. Faster than normal blood flow indicates anemia. In some cases, a procedure called cordocentesis may be performed to take a blood sample directly from the baby's umbilical cord. This confirms the diagnosis and measures the severity of anemia. Based on these findings, your medical team determines whether intrauterine transfusion is necessary and how urgently it should be performed.

Treatment approaches depend on the severity of fetal anemia and how far along the pregnancy is:

• Intrauterine transfusion to deliver healthy red blood cells directly to the baby
• Rh immunoglobulin injections for Rh-negative mothers to prevent sensitization
• Close monitoring with frequent ultrasounds and Doppler studies
• Early delivery if the baby is mature enough and anemia is worsening
• Phototherapy and exchange transfusions after birth if needed
• Intravenous immunoglobulin therapy in some cases
• Regular antibody level monitoring throughout pregnancy
• Coordination between maternal-fetal medicine specialists and neonatologists

Prevention is key for future pregnancies. Rh-negative mothers receive Rh immunoglobulin at 28 weeks of pregnancy and within 72 hours after delivery of an Rh-positive baby. This prevents the development of antibodies that could affect future pregnancies. Knowing your blood type and Rh factor before or early in pregnancy allows your healthcare team to create a proactive monitoring plan and intervene early if problems develop.